Sai Mirra Innopharm Private Limited

Sai Mirra Innopharm is a pharmaceutical company focused on developing and manufacturing Active Pharmaceutical Ingredients (APIs) and dosage formulations for global healthcare markets. Sai Mirra Innopharm Private Limited, founded in 2009, is located in Chennai, India, and specializes in the development of Active Pharmaceutical Ingredients (APIs) and dosage formulations. The company has successfully completed 1 deal, with the most recent deal occurring on April 29, 2025. The founder's specific history is not publicly available, and there are no mentions of subsidiaries or previous companies founded by the individuals involved.

Sai Mirra Innopharm is a fully integrated pharmaceutical company specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and dosage formulations. The company focuses on a diverse set of services including Contract Research Organization (CRO) activities and bio-equivalence studies, catering to both domestic and international markets. Their product portfolio is aimed at improving patient outcomes and quality of life, reflecting their commitment to quality and innovation. Sai Mirra's products are primarily utilized in the healthcare sector, serving pharmaceutical companies, healthcare providers, and ultimately, patients across over 55 countries globally, including markets in Europe, Asia, Africa, and North America.

The company's emphasis on research and development enables it to stay competitive and responsive to the evolving needs of the healthcare industry. Sai Mirra Innopharm generates revenue through direct sales of its pharmaceutical products and services to clients in the healthcare industry, including hospitals, pharmacies, and other healthcare providers. The company operates primarily in a B2B framework, establishing partnerships with other pharmaceutical companies and suppliers. Revenue is derived from the sales of both proprietary and generic formulations, with potential offerings tailored to meet specific client requirements.

The transaction structure typically involves bulk orders, supply agreements, and long-term contracts, ensuring continuous collaboration with their clients. As part of their service offerings, Sai Mirra may also engage in fee-for-service models for their CRO activities, further diversifying their revenue streams. In April 2025, Sai Mirra Innopharm secured INR 1. 6 billion in debt financing from Piramal Enterprises, which will support the company's brand acquisitions and broaden its product portfolio.

The company plans to enhance its offerings by designing new products targeted for launch within the next two years, while also aiming to expand its market presence in Europe and North America by the end of 2025.